Table 1.

Baseline demographics and disease characteristics (full analysis set)

Demographic variable	Group A (SPARTA/GEM/CIS) N = 33	Group B (SPARTA/PEM/CIS) N = 38	Group C (SPARTA/CARBO/PAC) N = 33	Group E (SPARTA/CAN/PEM/CIS) N = 7
Median age, years (IQR)	65.0 (57.0–68.0)	63.0 (58.0–69.0)	60.0 (55.0–68.0)	62.0 (57.0–72.0)
Age category (years), n (%)
18 to < 65	16 (48.5)	22 (57.9)	21 (63.6)	4 (57.1)
≥ 65	17 (51.5)	16 (42.1)	12 (36.4)	3 (42.9)
Sex, n (%)
Female	6 (18.2)	20 (52.6)	19 (57.6)	1 (14.3)
Male	27 (81.8)	18 (47.4)	14 (42.4)	6 (85.7)
ECOG PS, n (%)
0	8 (24.2)	13 (34.2)	10 (30.3)	1 (14.3)
1	25 (75.8)	24 (63.2)	23 (69.7)	6 (85.7)
Missing	0	1 (2.6)	0	0
Race, n (%)
Caucasian	26 (78.8)	26 (68.4)	28 (84.8)	5 (71.4)
Black	0	2 (5.3)	0	0
Asian	5 (15.2)	6 (15.8)	3 (9.1)	2 (28.6)
Native American	0	0	1 (3.0)	0
Other/Unknown	2 (6.0)	4 (10.5)	1 (3.0)	0
Histological subtype, n (%)
Adenocarcinoma	0	38 (100)	22 (66.7)	7 (100)
Squamous cell carcinoma	33 (100)	0	8 (24.2)	0
Other	0	0	3 (9.1)	0
Stage at initial diagnosis, n (%)
III	3 (9.1)	1 (2.6)	3 (9.1)	1 (14.3)
IV	28 (84.8)	33 (86.8)	23 (69.7)	6 (85.7)
Metastatic sites at baseline, n (%)
Lung	21 (63.6)	28 (73.7)	22 (66.7)	5 (71.4)
Lymph node	19 (57.6)	27 (71.1)	26 (78.8)	3 (42.9)
Liver	12 (36.4)	4 (10.5)	10 (30.3)	1 (14.3)
Bone	7 (21.2)	14 (36.8)	14 (42.4)	3 (42.9)
Pleura	5 (15.2)	8 (21.1)	7 (21.2)	3 (42.9)
Brain	2 (6.1)	6 (15.8)	9 (27.3)	0
Prior therapy, n (%)
Any therapy	28 (84.8)	31 (81.6)	27 (81.8)	7 (100)
Radiotherapy	4 (12.1)	10 (26.3)	12 (36.4)	2 (28.6)
Surgery (excluding biopsy)	2 (6.1)	2 (5.3)	4 (12.1)	2 (28.6)

CAN, canakinumab; CARBO, carboplatin; CIS, cisplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; GEM, gemcitabine; IQR, interquartile range; PAC, paclitaxel; PEM, pemetrexed; SPARTA, spartalizumab